Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN‐free therapy for HCV | Zendy

Toyoda Hidenori | Zendy; Kumada Takashi | Zendy; Tada Toshifumi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN‐free therapy for HCV

Author(s) -

Toyoda Hidenori,

Kumada Takashi,

Tada Toshifumi

Publication year - 2016

Publication title -

hepatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.488

H-Index - 361

eISSN - 1527-3350

pISSN - 0270-9139

DOI - 10.1002/hep.28632

Subject(s) - medicine , cirrhosis , hepatocellular carcinoma , incidence (geometry) , tolerability , gastroenterology , hepatitis c virus , hepatitis c , interferon , immunology , oncology , adverse effect , virus , physics , optics

JF, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. HEPATOLOGY 1997; 26:1115-1122. 3) Jirkovsky V, Fejfar T, Safka V, Hulek P, Krajina A, Chovanec V, et al. Influence of the secondary deployment of expanded polytetrafluoroethylene-covered stent grafts on maintenance of transjugular intrahepatic portosystemic shunt patency. J Vasc Interv Radiol 2011;22:55-60. CopyrightVC 2016 by the American Association for the Study of Liver Diseases.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research